CEO SUMMARY: Clinical laboratories of all sizes are poised to become the source of much of a hospital or health system’s “big data.” At many academic center labs, greater use of genetic and molecular testing requires that more space and more staff be devoted to data management. At the same time, the latest generation of gene sequencing instruments and molecular analyzers are cheaper, faster, and more automated. These systems make it feasible for even smaller labs to offer sophisticated genetic tests.
Tag: automated analyzer
CEO SUMMARY: As happens now and again, a rather typical example of an error in lab testing has made the nightly news in Indianapolis because of one justifiably irate patient who got a false positive test report for an STD. One pathologist, asked by THE DARK REPORT to assess the public information about this episode
CEO SUMMARY: Although GlaxoSmithKline PLC is several years away from having a deliverable product from its Antigen Specific Cancer Immunoassay (ASCI) Program, it has a development deal with Abbott Laboratories to produce a companion diagnostic test for ASCI-based products. The interesting twist in this arrangement is that the resulting companion diagnostic assay will be designed
CEO SUMMARY: Over the past two decades, investor-owned anatomic pathology companies captured significant market share from community hospital-based pathology groups while delivering profits to their owners. Despite the recent downturn in the economy, Wall Street believes histology laboratories remain an attractive investment for investors. Financial analyst Kemp Dolliver explains the reasons why professional investors remain
CEO SUMMARY: When 330-bed Botsford Hospital of Farmington Hills, Michigan, got interested in laboratory outreach 10 years ago, it brought in a new laboratory leader, invested in new analyzers and informatics, and then let the quality of the operation attract new business from the community. Today, Botsford’s outreach program performs 2.4 million tests per year